“Defensive” Switch Can Make Underperforming Rx An OTC Star – Consultant
This article was originally published in The Tan Sheet
Executive Summary
A proactive approach to moving drugs from Rx to OTC status through "defensive" switching will become increasingly important as drug cost containment efforts increase, according to NCI Consulting President Susan Lavine Coleman